Company intelligence / Profile preview

Fabentech

Lyon, Auvergne-Rhône-Alpes, Francefabentech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Fabentech develops and produces emergency immunotherapies based on its proprietary FabShield® polyclonal antibody fragment platform. The company’s pipeline includes antidotes for biological toxins and treatments for viral threats such as H5N1 influenza and COVID‑19. Programs range from proof of concept to clinical stage; some have completed development. The focus is rapid response to public health crises including pandemics and bioterror attacks.

Therapeutic areas: Infectious Diseases
Modalities: Polyclonal antibody fragments (immunotherapies)
Industry: Biotech

Drug pipeline

9 assets

FabenFLU

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Fabentech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fabentech.

Explore the full profile